PMID- 36561965
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221224
IS  - 1792-1015 (Electronic)
IS  - 1792-0981 (Print)
IS  - 1792-0981 (Linking)
VI  - 24
IP  - 6
DP  - 2022 Dec
TI  - Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer.
PG  - 749
LID - 10.3892/etm.2022.11685 [doi]
LID - 749
AB  - Anti-programmed cell death protein-1 (PD-1)/programmed cell death 1 ligand 1 
      (PD-L1) antibodies have been widely used in cancers. The present study aimed to 
      evaluate the efficacy and safety of PD-1/PD-L1 inhibitors in human cancers. 
      Studies were searched from Cochrane Library, PubMed and Embase databases. 
      Randomized controlled trials (RCTs) that investigated adjuvant therapy with 
      anti-PD-1/PD-L1 agents in solid cancers were eligible for inclusion. As the 
      primary focus of the meta-analysis, clinical outcome measures including overall 
      survival (OS), disease-free survival (DFS), and adverse events (AEs) were 
      analyzed by Stata 15.0 software. A total of six RCTs (n=4,436) met the inclusion 
      criteria. The DFS [hazard ratio (HR)=0.71; 95% confidence interval (CI): 
      0.63-0.78; P<0.001] and OS (HR=0.66, 95% CI: 0.46-0.86, P<0.001) of patients were 
      significantly prolonged by adjuvant immunotherapy. Subgroup analysis indicated 
      that significantly improved DFS was observed in patients treated with different 
      anti-PD-1/PD-L1 drugs (nivolumab, pembrolizumab, or atezolizumab), as well as in 
      those with different tumors (melanoma, urothelial carcinoma, esophageal or 
      gastroesophageal junction cancer, or renal cell carcinoma), and PD-L1 status 
      [negative (<1%) or positive (>/=1%)]. However, PD-1/PD-L1 inhibitors was associated 
      with increased >/= grade 3 treatment-related AEs (odds ratio=1.63; 95% CI: 
      1.20-2.21; P=0.002). The available evidence suggests that adjuvant therapy with 
      PD-1/PD-L1 inhibitors provided more survival benefit than placebo for patients 
      with cancer, with increased grade 3 or higher AEs. Prospero registration no. 
      CRD42021290654.
CI  - Copyright: (c) Mo et al.
FAU - Mo, Dun-Chang
AU  - Mo DC
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530000, P.R. China.
FAU - Liang, Zi-Yu
AU  - Liang ZY
AD  - Department of Gastroenterology, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530000, P.R. China.
FAU - Chen, Long
AU  - Chen L
AD  - Ear, Nose and Throat and Head and Neck Surgery Department, The Third Affiliated 
      Hospital of Guangxi Medical University, Nanning, Guangxi 530000, P.R. China.
FAU - Huang, Jian-Feng
AU  - Huang JF
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530000, P.R. China.
FAU - Luo, Peng-Hui
AU  - Luo PH
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530000, P.R. China.
FAU - Wang, Han-Lei
AU  - Wang HL
AD  - Radiotherapy Department, The Third Affiliated Hospital of Guangxi Medical 
      University, Nanning, Guangxi 530000, P.R. China.
LA  - eng
PT  - Journal Article
DEP - 20221108
PL  - Greece
TA  - Exp Ther Med
JT  - Experimental and therapeutic medicine
JID - 101531947
PMC - PMC9748656
OTO - NOTNLM
OT  - adjuvant immunotherapy
OT  - immune checkpoint inhibitor
OT  - meta-analysis
OT  - programmed cell death protein-1/programmed cell death 1 ligand 1
COIS- The authors declare that they have no competing interests.
EDAT- 2022/12/24 06:00
MHDA- 2022/12/24 06:01
PMCR- 2022/11/08
CRDT- 2022/12/23 02:40
PHST- 2022/06/17 00:00 [received]
PHST- 2022/08/22 00:00 [accepted]
PHST- 2022/12/23 02:40 [entrez]
PHST- 2022/12/24 06:00 [pubmed]
PHST- 2022/12/24 06:01 [medline]
PHST- 2022/11/08 00:00 [pmc-release]
AID - ETM-24-6-11685 [pii]
AID - 10.3892/etm.2022.11685 [doi]
PST - epublish
SO  - Exp Ther Med. 2022 Nov 8;24(6):749. doi: 10.3892/etm.2022.11685. eCollection 2022 
      Dec.